TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04998279

Intervention type: DRUG
Intervention: Granulocyte Colony-Stimulating Factor
Description: Granulocyte-colony stimulating factors (G-CSF) is synthesized in the reproductive tract naturally, it is a hematopoietic lineage-specific cytokine which is known for its specific effects on the activation of intracellular signaling pathways that are associated with the cell proliferation, differentiation, and stimulation of hematopoietic cells of the neutrophilic granulocyte lineage; which act on macrophages of decidual cells and finally affect implantation

Intervention type: OTHER
Intervention: placebo
Description: mock test without injection of G-CSF
Study: NCT02678767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
Study: NCT00068380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02891239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay
Description: solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
Study: NCT01901354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-tidal-volume ventilation
Description: Goal tidal volume is 6 cc/kg ideal body weight.
Study: NCT00571558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo photodynamic therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01065493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QuitAdvisorMD Software Algorithm
Description: QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Smoking Cessation Counseling
Description: Standard Smoking Cessation Counseling
Study: NCT02874248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 mg E4/3 mg DRSP
Description: a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mg E4/6 mg DRSP
Description: a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg E4/12 mg DRSP
Description: a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visually matching placebo
Description: a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Visually matching placebo
Description: a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Visually matching placebo
Description: a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Visually matching placebo
Description: a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75 mg E4/15 mg DRSP
Description: a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
Study: NCT00540384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Description: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Study: NCT01901354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airway Pressure Release Ventilation (APRV)
Description: APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
Study: NCT00622661

Intervention type: OTHER
Group type: OTHER
Intervention: Low Glycemic Load Diet
Description: consume both high and low glycemic load diets for 28 days each

Intervention type: OTHER
Group type: OTHER
Intervention: Low Glycemic Load Diet
Description: consume both high and low glycemic load diets for 28 days each

Intervention type: OTHER
Group type: OTHER
Intervention: High Glycemic Load Diet
Description: consume both high and low glycemic load diets for 28 days each

Intervention type: OTHER
Group type: OTHER
Intervention: High Glycemic Load Diet
Description: consume both high and low glycemic load diets for 28 days each
Study: NCT02683382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moisturizing Eye Product in Liquid Formula
Description: Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizing Eye Product in Liquid Formula
Description: Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
Study: NCT03421314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate and/or Selenium yeast
Description: 30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate and/or Selenium yeast
Description: 30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate and/or Selenium yeast
Description: 30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast
Study: NCT00797628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decide2Quit
Description: Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Coach
Description: Control Patients will be referred by paper prescription to the control- Smoking Coach website.
Study: NCT00893165

Intervention type: BEHAVIORAL
Intervention: moderate physical activity
Description: bed mounted cycles for physical activity for 30 min during each hemodialysis session
Study: NCT03256058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reinflation after early deflation
Description: the tourniquet would be inflated immediately before incision and deflated after the use of the cement , and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation. The total time of tourniquet inflation is controlled within 90 minutes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
Study: NCT01639547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Ribavirin
Description: Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000\~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Ribavirin
Description: Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000\~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
Study: NCT03628989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Virtual Technology
Description: If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Virtual Technology
Description: If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
Study: NCT01179841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playgroup
Description: The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Training
Description: The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
Study: NCT02952846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm for tapering og analgosedation
Description: Algorithm for tapering og analgosedation
Study: NCT03408470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 oral capsule
Description: (Intervention description included in arm description)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TD-1473 IV bolus
Description: (Intervention description included in arm description)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TD-1473 Oral Capsule
Description: (Intervention description included in arm description)
Study: NCT03087097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (MAM or SAM) who are in the rehabilitation phase of treatment and have failed to respond to at least 4 weeks of standard therapy.
Study: NCT04143594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections
Study: NCT00540384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Description: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Description: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Description: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Study: NCT00733577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB756050
Description: doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB756050
Description: doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB756050
Description: doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB756050
Description: doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
Study: NCT02636751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week prehabilitation program
Description: stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week prehabilitation program
Description: stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
Study: NCT04143594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF
Description: Tablets administered without regard to food
Study: NCT00110227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Tai Chi Program
Description: 24 tai chi sessions. 2 sessions/week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-week Education Program
Description: 24 Educational sessions. 2 sessions/week for 12 weeks.
Study: NCT00831974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: 3 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: 6 mg/kg/day
Study: NCT00733239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-4 of the drugs listed below
Description: Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
Study: NCT02063945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: As stated in arm/group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: As stated in arm/group
Study: NCT03190668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus dose of Cefazolin
Description: Mode of Cefazolin administration will be a intermittent bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Cefazolin drip
Description: Mode of Cefazolin administration will be a continuous drip

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paraspinal muscle microdialysis catheters
Description: Two dialysis probes will be inserted into a paraspinal muscle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paraspinal muscle microdialysis catheters
Description: Two dialysis probes will be inserted into a paraspinal muscle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous microdialysis catheters
Description: Two dialysis probes will be inserted into a paraspinal subcutaneous region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous microdialysis catheters
Description: Two dialysis probes will be inserted into a paraspinal subcutaneous region
Study: NCT00831714

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made

Intervention type: DRUG
Intervention: Standard care treatment for VTE prophylaxis
Description: Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
Study: NCT02101931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino levulinic Acid
Description: The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
Study: NCT02416128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euphrasia
Description: 1 drop in the treated eye QID X 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate
Description: 1 drop in the treated eye QID X 10 days
Study: NCT03152331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receptive Awareness Training
Description: Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
Study: NCT00877409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide 5% and Sulphur 2%
Description: The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Acnase
Description: The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.